Without question, advanced cellular and gene therapies require well-defined cold-chain management solutions that reduce risk and include all elements of packaging, data collection and logistics expertise to ensure high-quality, effective treatments reach the point of care, and ultimately, the patient.
Evaluating the use of new tumor measurement tools for studies of molecular-targeted cancer therapies.
Why the requirement for the collection of cardiac safety data?
ICON announced that its clinical research unit in San Antonio is a certified and preferred site in iCardiac’s Early Precision QT Program.
PRA's new bioanalytical laboratory in Netherlands features more space and equipment for large and small molecules.
With this technology in place, INC may be able to eliminate the need for a separate, dedicated Thorough QT (TQT) studies.
INTERLAB and synlab have been successfully cooperating since 2004.
Tufts CSDD finds drug and diagnostics companies are investing in the development of companion diagnostics that can show that their use in conjunction with personalized therapeutics will lead to positive health outcomes.